Lake Street Capital Cuts Femasys (NASDAQ:FEMY) Price Target to $10.00

Femasys (NASDAQ:FEMY) had its price objective cut by Lake Street Capital to $10.00 in a research report released on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities research analysts have also commented on FEMY. Wall Street Zen upgraded shares of Femasys to a “hold” rating in a report on Saturday, June 13th. Maxim Group lowered their target price on Femasys to $10.00 and set a “buy” rating for the company in a report on Friday, August 14th. Finally, Weiss Ratings raised Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Femasys has an average rating of “Moderate Buy” and a consensus target price of $50.00.

Femasys Stock Performance

Shares of FEMY stock opened at $2.73 on Tuesday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.98 and a current ratio of 2.14. The company has a market capitalization of $8.24 million, a P/E ratio of -0.77 and a beta of -2.08. The company’s 50 day moving average price is $3.39 and its two-hundred day moving average price is $7.03. Femasys has a 52 week low of $2.02 and a 52 week high of $22.20.

Femasys (NASDAQ:FEMY) last announced its quarterly earnings results on Friday, August 14th. The company reported ($1.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.02). The company had revenue of $0.33 million during the quarter, compared to the consensus estimate of $0.73 million. Femasys had a negative net margin of 534.36% and a negative return on equity of 225.97%.

Insider Activity at Femasys

In other Femasys news, CFO Dov Elefant acquired 15,625 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were acquired at an average price of $3.20 per share, with a total value of $50,000.00. Following the completion of the transaction, the chief financial officer directly owned 15,625 shares in the company, valued at $50,000. This trade represents a ? increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Kathy Lee-Sepsick acquired 15,625 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was acquired at an average cost of $3.20 per share, for a total transaction of $50,000.00. Following the transaction, the chief executive officer owned 15,625 shares of the company’s stock, valued at $50,000. This represents a ? increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 38,750 shares of company stock valued at $124,000 over the last ninety days. Company insiders own 7.75% of the company’s stock.

Institutional Investors Weigh In On Femasys

Several hedge funds and other institutional investors have recently added to or reduced their stakes in FEMY. Cetera Investment Advisers bought a new stake in Femasys during the 4th quarter worth about $36,000. Kovack Advisors Inc. bought a new position in shares of Femasys in the 4th quarter valued at about $27,000. State Street Corp increased its position in shares of Femasys by 43.5% in the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock valued at $47,000 after acquiring an additional 24,500 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Femasys in the fourth quarter valued at about $62,000. Finally, HRT Financial LP bought a new stake in Femasys during the fourth quarter worth about $30,000. 65.27% of the stock is currently owned by institutional investors and hedge funds.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.